We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Iceni Labs is an innovative enterprise that develops and deploys cutting-edge technologies to build a safer and secure future. The company takes early-stage technology from the lab to the market by partnering with leading academics, researchers, and commercial experts. It has collaborated with the UK National Health Service’s (NHS) Royal Papworth Hospital to accelerate the development of a non-contact device, SafeScan, that monitors the breathing rate of an individual remotely. Iceni Labs also conducted a one-year clinical study of the device at Royal Papworth Hospital on a sample size of 400 patients. It has been awarded Innovate UK funding to build a prototype for monitoring care home residents. The company's goal is to become globally recognised as a catalyst for successful innovation.
days to go: Expired investment: Withheld
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go: Expired investment: £1,149,999
Intoware provide wearable, mobile and desktop technology to SME's and SAS clients. Intoware digitise the deskless workspace and therefore remove the need for paper checklists. Once a checklist is complete, Intoware is able to share the completed list with anyone it may concern.
days to go: Expired investment: £700,000
Jobhawk is the UK’s first digital marketplace for construction labour. They aim to make it possible for sub-contractors to get self-employed labour instantly for their projects. They have developed an app that matches the UK's leading subcontractors with bricklayers, carpenters and other tradesmen, with less effort for everyone involved.
days to go: Expired investment: £728,573
Kaleao has created simple, agile and flexible hardware and software systems which provide 10x more performance per unit of space and consumes 4x less energy. They maintain all promises of the hyperconvergence through the convergence of compute, storage and networking hardware whilst teamed with a full-featured and flexible software platform.
days to go: Expired investment: £2,050,000
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go: Expired investment: Withheld
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
Walljam is a sports technology business that is digitising ball sports through its advanced, smart panel technology. The company's latest offering, 'Metrix', is the first football-themed social entertainment venue launched in partnership with UEFA Champions League. Walljam intends Metrix to be the turning point in the company's image from a purely fan engagement platform to a social entertainment and live events operator. Metrix's inaugural venue will open in Autumn 2020 at Westfield London (White City), Europe’s largest shopping mall. Under the UEFA Global Licensing Partnership, nine more venues are expected to open across Europe within the next five years. The company is seeking to raise funds of £3.5 million at a pre-money valuation of £3.6 million. It will use the investment to launch the first Metrix venue and manage working capital.
days to go: Expired investment: £577,132
MyCustomerLens uses artificial intelligence to connect and summarise customer feedback garnered from multiple sources such as surveys, online reviews, interviews on its real-time feedback aggregation platform. MyCustomerLens argues survey providers, research agencies, and online reviews collect disconnected data. It further points out that their cumulative outputs get stuck in silos and are rarely updated, which firms find cumbersome and time-consuming. MyCustomerLens claims that its portal provides actionable insights firms need to protect and grow their revenues in the wake of remote working and digital transformations brought forth by Covid-19. MyCustomerLens aspires to dominate the estimated $23 billion Customer Experience Management (CEM) market by 2027. It asserts that its targeted businesses are the UK's 26,000 legal, accounting and consulting firms, with banking and healthcare firms in the pipeline. MyCustomerLens states they will use the investment to expand their core team and enable investments in marketing and partnerships that will accelerate its growth.
days to go: Expired investment: Withheld
Netflix, Inc. is an American media service provider and production company founded in 1997 by Reed Hastings and Marc Randolph in Scotts Valley, California. It has 100 million members in over 190 countries enjoying more than 125 million hours of TV programmes and films per day. In 2017, the company's project 'The White Helmets' won the Academy Award for Best Documentary (Short Subject). For the fiscal year 2019, the company's annual net income was $1.9 billion, up 54.1% Year-over-Year (YOY). The company has won a list of accolades such as the Academy Awards, Golden Globe Awards, BAFTA Film Awards, Grammy Awards, and Daytime Emmy Awards, to name a few. It will use the investment to grow its business across different verticals. 
days to go: Expired investment: £844,200
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph